http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yiqun Du (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Winding strategy of driving cable based on dynamic analysis of deployment for deployable antennas
Yiqun Zhang,Dongwu Yang,Zihan Sun,Na Li,Jianghua Du 대한기계학회 2019 JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY Vol.33 No.11
An optimization method for the winding strategy of the driving cable is proposed based on a dynamic analysis of the AstroMesh antenna deployment. First, considering the effects of the cable net and friction, the driving force for deployment is deduced according to energy conservation. Thereafter, an optimization model is constructed, with the objective of minimum deployment driving power, using design variables consisting of control parameters of the winding length curve of the driving cable; this curve is described by the Bezier curve. Moreover, corresponding to the winding process of the driving cable before and after optimization, deployment experiments for a 2-m aperture deployable antenna prototype are conducted. Finally, the validity and rationality of the optimization method are verified by comparing the simulation and experimental results.
-
Ying Lin,Mingxi Lin,Jian Zhang,Biyun Wang,Zhonghua Tao,Yiqun Du,Sheng Zhang,Jun Cao,Leiping Wang,Xichun Hu 대한암학회 2020 Cancer Research and Treatment Vol.52 No.4
Purpose Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), focusing on efficacy in lapatinib-treated patients and in brain metastasis. Materials and Methods One hundred thirteen patients with metastatic HER2-positive BC treated with pyrotinib-based therapy in Fudan University Shanghai Cancer Center under non-clinical trial settings from September 1, 2018 to March 1, 2019 were included. Results Over half patients have received more than two lines of systematic therapy and exposed to two or more kinds of anti-HER2 agents. Most patients received a combined therapy, commonly of pyrotinib plus capecitabine, or vinorelbine or trastuzumab. Median progression-free survival (PFS) was 6.3 months (range, 5.54 to 7.06 months) and objective response rate (ORR) was 29.5%, with two patients (1.9%) achieving complete response. Lapatinib-naïve patients had significantly longer PFS than lapatinib-treated patients (9.0 months vs. 5.4 months, p=0.001). ORR for lapatinib-treated patients was 23.2%. Thirty-one of 113 patients have brain metastasis. Median PFS was 6.7 months and intracranial ORR was 28%. For patients without concurrent radiotherapy and/or brain surgery, the ORR was very low (6.3%). But for patients receiving concurrent radiotherapy and/or brain surgery, the ORR was 66.7%, and three patients achieved complete response. Most common adverse event was diarrhea. Conclusion Pyrotinib-based therapy demonstrated promising effects in metastatic HER2-positive BC and showed activity in lapatinib-treated patients. For patients with brain metastasis, pyrotinib-based regimen without radiotherapy showed limited efficacy, but when combined with radiotherapy it showed promising intracranial control.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
